# Ocrevus (ocrelizumab)

Type: Product (RHHBY)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/ocrevus-ocrelizumab
Canonical HTML page: https://gethealthbrief.com/entity/ocrevus-ocrelizumab

## Recent coverage (1 stories)

### MS Patients Face $33K/Year Without PBS as Review Eyes 50% Price Cut
2026-07-15 21:43:35 · Sentiment: Bearish · Impact: 7/10 · Sources: 11

Two of Australia’s most used MS therapies, Ocrevus and Kesimpta, face a PBS pricing review that could slash subsidies by 40–50%. Without coverage, patients could pay over $33,000 annually, jeopardizing treatment access for thousands.
Full story: https://gethealthbrief.com/story/pbs-ms-treatments-review-health

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.